Presented by 3C Integrity managing director Christoph Kr?henbühl (pic) in association with pharmaceutical coding specialist Sunala, the seminar will demonstrate how, although certain aspects of the directive will not be known until 2014, there is enough information available for companies to begin their preparations now and that those who delay for too long run the risk of not being ready in time.
The threat of falsified medicines penetrating the European pharmaceutical supply chain is substantial and growing and the FMD has been established as an important step in protecting patients from counterfeit medicines.
While the exact outcome of the Delegated Acts is not expected until next year, there are clear indications of what will be required, in particular the need for all companies to participate in a systems-based, Europe-wide medicines verification process.
